Cite
Miller RG, Block G, Katz JS, et al. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e100doi: 10.1212/NXI.0000000000000100.
Miller, R. G., Block, G., Katz, J. S., Barohn, R. J., Gopalakrishnan, V., Cudkowicz, M., Zhang, J. R., McGrath, M. S., Ludington, E., Appel, S. H., Azhir, A. (2015). Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurology(R) neuroimmunology & neuroinflammation, 2(3), e100. https://doi.org/10.1212/NXI.0000000000000100
Miller, Robert G, et al. "Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS." Neurology(R) neuroimmunology & neuroinflammation vol. 2,3 (2015): e100. doi: https://doi.org/10.1212/NXI.0000000000000100
Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm. 2015 Apr 09;2(3):e100. doi: 10.1212/NXI.0000000000000100. eCollection 2015 Jun. PMID: 25884010; PMCID: PMC4396529.
Copy
Download .nbib